Compassionate Use of NHWD-870 for NUT-Positive Tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial offers early access to an experimental drug called NHWD-870 for people with advanced solid tumors or lymphomas that have a specific genetic change called a NUT rearrangement. The goal is to see if this drug can help shrink or slow the growth of these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of an advanced solid tumor or lymphoma that cannot be cured with standard treatments.
- Your tumor must test positive for a NUT rearrangement, which is a specific genetic change.
- You must be between 18 and 75 years old.
- You must be well enough to be up and about (ECOG score 0 or 1), meaning you can care for yourself and do daily activities.
- You must not have other serious health problems like uncontrolled infections, recent heart attack, high blood pressure, or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NHWD-870 for people with NUT cancer (a rare cancer linked to a gene change). The goal is to see if the drug can help shrink tumors or slow the cancer's growth.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
This trial tests a new drug, AWT020, for people with advanced cancer (solid tumors or lymphoma) that hasn't responded to other treatments. The goal is to see if it is safe and how well it works.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug called LNF2105 in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called Nectin-4 found on many cancer cells, and researchers want to see if LNF2105 can help shrink or control these tumors.
Hear when a new Advanced Solid Tumors or Lymphomas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.